Literature DB >> 26903060

[Change in serum follistatin-like protein 1 and its clinical significance in children with chronic heart failure].

Bing-Lu Li1, Jin-Dou An, Song Feng, Wei Ge.   

Abstract

OBJECTIVE: To investigate the change in the serum level of follistatin-like protein 1 (FSTL1) in children with chronic heart failure and its correlation with left ventricular remodeling.
METHODS: A total of 45 children with chronic heart failure (CHF) between May 2014 and May 2015 were selected as the CHF group, among whom 21 had endocardial fibroelastosis (EFE) and 24 had dilated cardiomyopathy (DCM); another 30 healthy children were selected as the control group. Enzyme-linked immunosorbent assay was applied to measure the serum level of FSTL1. Radioimmunoassay was applied to measure N-terminal pro-brain natriuretic peptide, and echocardiography was applied to measure the indicators of left ventricular remodeling. The correlation between the serum level of FSTL1 and left ventricular remodeling was analyzed by Pearson correlation and Spearman′s rank correlation analysis.
RESULTS: Before treatment, the CHF group had a significantly higher serum level of FSTL1 than the control group (P<0.05), which gradually increased with aggravation of CHF (P<0.05). The serum level of FSTL1 showed no significant difference between the EFE and DCM groups (P=0.176). Serum level of FSTL1 was positively correlated with left ventricular end-diastolic diameter (r=0.485, P=0.001), left ventricular mass (r=0.322, P=0.031), left ventricular mass index (r=0.353, P=0.017), and N-terminal pro-brain natriuretic peptide (r=0.562 P<0.001), and was negatively correlated with left ventricular ejection fraction (r=-0.436, P=0.003) and left ventricular minor axis decurtation rate (r=-0.436, P=0.003).
CONCLUSIONS: FSTL1 might take part in the left ventricular remodeling in children with CHF, and the serum level of FSTL1 can be used as an objective index for clinical diagnosis and severity assessment of CHF in children.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26903060      PMCID: PMC7403043     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  12 in total

1.  Expression of follistatin-related genes is altered in heart failure.

Authors:  Enrique Lara-Pezzi; Leanne E Felkin; Emma J Birks; Padmini Sarathchandra; Kalyani D Panse; Robert George; Jennifer L Hall; Magdi H Yacoub; Nadia Rosenthal; Paul J R Barton
Journal:  Endocrinology       Date:  2008-07-10       Impact factor: 4.736

2.  The left atrial phasic functions and the relationship with plasma N-terminal pro-B-type natriuretic peptide levels and symptomatic states in patients with hypertrophic cardiomyopathy.

Authors:  Kamil Tülüce; Selcen Yakar Tülüce; Oğuz Yavuzgil; Elnur İsayev; Murat Bilgin; Filiz Akyıldız Akçay; Sanem Nalbantgil; Filiz Özerkan
Journal:  Anadolu Kardiyol Derg       Date:  2014-02-10

3.  Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling.

Authors:  Ali El-Armouche; Noriyuki Ouchi; Komei Tanaka; Gheorghe Doros; Katrin Wittköpper; Thomas Schulze; Thomas Eschenhagen; Kenneth Walsh; Flora Sam
Journal:  Circ Heart Fail       Date:  2011-05-27       Impact factor: 8.790

4.  Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome.

Authors:  Christian Widera; Evangelos Giannitsis; Tibor Kempf; Mortimer Korf-Klingebiel; Beate Fiedler; Sarita Sharma; Hugo A Katus; Yasuhide Asaumi; Masayuki Shimano; Kenneth Walsh; Kai C Wollert
Journal:  Clin Chem       Date:  2012-06-06       Impact factor: 8.327

5.  Natural history and prognostic risk factors in endocardial fibroelastosis.

Authors:  T Ino; L N Benson; R M Freedom; R D Rowe
Journal:  Am J Cardiol       Date:  1988-09-01       Impact factor: 2.778

6.  Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models.

Authors:  Yasuhiro Ogura; Noriyuki Ouchi; Koji Ohashi; Rei Shibata; Yoshiyuki Kataoka; Takahiro Kambara; Tetsutaro Kito; Sonomi Maruyama; Daisuke Yuasa; Kazuhiro Matsuo; Takashi Enomoto; Yusuke Uemura; Megumi Miyabe; Masakazu Ishii; Takashi Yamamoto; Yuuki Shimizu; Kenneth Walsh; Toyoaki Murohara
Journal:  Circulation       Date:  2012-08-28       Impact factor: 29.690

7.  An immunomodulatory role for follistatin-like 1 in heart allograft transplantation.

Authors:  J B Le Luduec; T Condamine; C Louvet; P Thebault; J-M Heslan; M Heslan; E Chiffoleau; M-C Cuturi
Journal:  Am J Transplant       Date:  2008-11       Impact factor: 8.086

8.  Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart.

Authors:  Yuichi Oshima; Noriyuki Ouchi; Kaori Sato; Yasuhiro Izumiya; David R Pimentel; Kenneth Walsh
Journal:  Circulation       Date:  2008-06-02       Impact factor: 29.690

Review 9.  The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.

Authors:  George Karayannis; Filippos Triposkiadis; John Skoularigis; Panagiotis Georgoulias; Javed Butler; Gregory Giamouzis
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 10.  In search of new therapeutic targets and strategies for heart failure: recent advances in basic science.

Authors:  Ajay M Shah; Douglas L Mann
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

View more
  1 in total

Review 1.  Follistatin-like 1 in development and human diseases.

Authors:  Andrea Mattiotti; Stuti Prakash; Phil Barnett; Maurice J B van den Hoff
Journal:  Cell Mol Life Sci       Date:  2018-03-29       Impact factor: 9.261

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.